Sorafenib, Cabozantinib, Lenvatinib, and Regorafenib are some commonly available drugs for HBV-associated HCC that target various targets including the vascular endothelial growth factor (VEGF), platelet-derived growth factor receptors (PDGFRs), epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) respectively (139). This evidence concerns the gene EGFR and hepatocellular carcinoma.